Core Viewpoint - GDS Holdings (GDS) has shown a significant price increase of 14.4% over the past four weeks, with a mean price target of $44.17 indicating a potential upside of 25.2% from the current price of $35.27 [1] Price Targets and Analyst Consensus - The average price target for GDS includes 12 estimates ranging from a low of $28.30 to a high of $64.54, with a standard deviation of $9.75, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 19.8%, while the highest points to an 83% upside potential [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about GDS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 5.1% over the past month, with one estimate increasing and no negative revisions [12] - GDS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to historical inaccuracies in predicting actual stock movements [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8] - Despite the skepticism surrounding price targets, the direction they imply can still serve as a useful guide for potential stock movements [14]

Core Viewpoint - Dyne Therapeutics, Inc. (DYN) shows significant upside potential with a mean price target of $38.21, indicating a 285.6% increase from the current trading price of $9.91 [1] Price Targets and Estimates - The mean estimate consists of 17 short-term price targets with a standard deviation of $14.79, suggesting variability in analyst predictions. The lowest estimate is $9.00 (9.2% decline), while the highest is $66.00 (566% increase) [2] - Analysts' price targets can be misleading, as empirical research indicates they rarely accurately predict stock price movements [7][10] Earnings Estimates - Analysts have shown increasing optimism regarding DYN's earnings, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 6.1%, with four estimates moving higher and no negative revisions [12] Analyst Rankings - DYN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of DYN's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Zevra Therapeutics (ZVRA) has seen a 16.8% increase in share price over the past four weeks, closing at $10.99, with analysts suggesting a potential upside of 117.1% based on a mean price target of $23.86 [1][4]. Price Targets and Analyst Estimates - The mean price target is derived from seven short-term estimates with a standard deviation of $3.39, indicating a range of potential outcomes; the lowest estimate is $19.00 (72.9% increase), while the highest is $29.00 (163.9% increase) [2][9]. - A low standard deviation among price targets suggests a strong consensus among analysts regarding the stock's price direction, although it does not guarantee that the stock will reach the average target [9][10]. Earnings Estimates and Market Sentiment - Analysts are optimistic about ZVRA's earnings prospects, as indicated by a significant increase in earnings estimate revisions, with a 337.1% rise in the Zacks Consensus Estimate for the current year [11][12]. - ZVRA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential for near-term upside [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the positive direction indicated by earnings estimate revisions appears to be a valid guide for potential stock price movements [14].

Group 1 - Shares of uniQure (QURE) have increased by 1.3% over the past four weeks, closing at $14.46, with a mean price target of $35.09 indicating a potential upside of 142.7% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $17.1, where the lowest estimate is $13.00 (10.1% decline) and the highest is $70.00 (384.1% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions suggesting potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1% due to one upward revision in the last 30 days, with no negative revisions [12] - QURE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Analyst recommendations play a significant role in influencing stock prices, but their reliability is questionable, particularly for Netflix (NFLX) [1][5]. Brokerage Recommendations - Netflix has an average brokerage recommendation (ABR) of 1.75, indicating a consensus between Strong Buy and Buy, based on 46 brokerage firms [2]. - Out of the 46 recommendations, 28 are Strong Buy (60.9%) and 3 are Buy (6.5%) [2]. Limitations of Brokerage Recommendations - Solely relying on ABR for investment decisions may not be advisable, as studies indicate that brokerage recommendations often fail to guide investors effectively [5]. - Analysts from brokerage firms tend to exhibit a positive bias due to vested interests, leading to a disproportionate number of favorable ratings compared to negative ones [6][10]. Zacks Rank as an Alternative - Zacks Rank, a proprietary stock rating tool, categorizes stocks from Strong Buy to Strong Sell and is based on earnings estimate revisions, which correlate strongly with stock price movements [8][11]. - The Zacks Rank is distinct from ABR; while ABR is based on brokerage recommendations, Zacks Rank utilizes quantitative models and is updated more frequently [9][12]. Current Earnings Estimates for Netflix - The Zacks Consensus Estimate for Netflix's earnings has increased by 2.9% over the past month to $26.06, reflecting analysts' growing optimism [13]. - This increase in consensus estimates, along with other factors, has resulted in a Zacks Rank of 1 (Strong Buy) for Netflix, suggesting a potential for stock appreciation [14].

Check price target & stock forecast for Robinhood Markets here>>> While the ABR calls for buying Robinhood Markets, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-fi ...

Group 1 - Analysts forecast PSEG (PEG) will report quarterly earnings of $0.71 per share, reflecting a year-over-year increase of 12.7% [1] - Anticipated revenues for the quarter are $2.34 billion, showing a decrease of 3.2% compared to the previous year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1] Group 2 - Revenue for PSE&G is expected to reach $1.97 billion, indicating a year-over-year change of +5.6% [3] - Revenue from Power & Other is projected at $453.29 million, representing a decline of -33.7% from the prior-year quarter [4] - The consensus estimate for total gas sold and transported is 543 million dekatherm, slightly down from 550 million dekatherm a year ago [4] Group 3 - Analysts estimate 'Gas Sold and Transported - Total Non-Firm Sales' at 176 million dekatherm, down from 191 million dekatherm in the previous year [5] - 'Gas Sold and Transported - Total Firm Sales' is expected to be 366 million dekatherm, compared to 359 million dekatherm reported last year [6] - Operating Income for Power & Other is forecasted to be $72.68 million, down from $115.00 million in the prior year [6] Group 4 - Operating Income for PSE&G is projected to reach $527.13 million, an increase from $467.00 million reported last year [7] - PSEG shares have increased by +9.4% in the past month, outperforming the Zacks S&P 500 composite's +2.7% [7] - PSEG holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [7]

Guardant Health (GH) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.48 per share a year ago. These figures are adjusted for non- recurring items. While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earning ...

Investors might want to bet on Sendas Distribuidora S.A. Sponsored ADR (ASAIY) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus E ...

Core Viewpoint - West Pharmaceutical Services (WST) has shown a significant price increase of 13.7% over the past four weeks, with analysts projecting a mean price target of $316.82, indicating a potential upside of 25.3% from the current price of $252.94 [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $34.23, suggesting variability in analyst predictions. The lowest estimate is $260.00 (2.8% increase), while the highest is $355.00 (40.4% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding WST's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. Four estimates have increased over the last 30 days, with no negative revisions, leading to a 7.8% increase in the Zacks Consensus Estimate [11][12] - WST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead. Empirical research suggests that price targets rarely indicate actual stock price movements, and analysts may set overly optimistic targets due to business incentives [7][8][10]